New MS Drug Ocrevus Wins FDA Approval
Teva Pharmaceuticals - Wikipedia
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Teva Pharmaceutical Facing EU Antitrust Investigation Over Patent Strategy for MS Drug - IP News Shots
Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | FiercePharma
Teva embroiled in Copaxone dosage levels dispute - Globes
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Hope In A Pill
US regulator backs copycat version of Teva MS drug | Financial Times
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
18. Teva Pharmaceutical Industries | FiercePharma
New MS Drug Ocrevus Wins FDA Approval
FDA approves first generic version of epilepsy drug Sabril from Teva
Teva faces EU antitrust probe over MS drug Copaxone -
Teva's MS Drug Copaxone Looking for Approval in Japan - Jewish Business News
Another setback for Teva's laquinimod in MS - PMLiVE
What are the implications of a generic Teva MS drug? Here's what the wags say - STAT
Teva Pays $925,000 to Settle Mississippi Drug-Price Case, Seek More Pacts - Bloomberg
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Pioglitazone Could Play a Role in MS Treatment | Everyday Health
Teva knocked as competition fears grow for MS drug | Financial Times
![Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)](https://mma.prnewswire.com/media/1019389/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Bioequ.jpg "Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)")
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | FiercePharma
U.S. sues Teva over alleged kickbacks for multiple sclerosis drug | Reuters
Generic drugs giant Teva to cut workforce by more than 25%
